Analyzing Bluejay Diagnostics (NASDAQ:BJDX) and TransMedics Group (NASDAQ:TMDX)

Bluejay Diagnostics (NASDAQ:BJDX) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.

Insider and Institutional Ownership

18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 0.1% of Bluejay Diagnostics shares are owned by insiders. Comparatively, 6.9% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Bluejay Diagnostics and TransMedics Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-144.27%	-115.00%
TransMedics Group	27.04%	22.38%	8.46%

Analyst Ratings

This is a summary of recent ratings for Bluejay Diagnostics and TransMedics Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1	0	0	0	1.00
TransMedics Group	0	7	6	0	2.46

TransMedics Group has a consensus price target of $134.00, indicating a potential upside of 83.79%. Given TransMedics Group’s stronger consensus rating and higher possible upside, analysts clearly believe TransMedics Group is more favorable than Bluejay Diagnostics.

Volatility and Risk

Bluejay Diagnostics has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500.

Valuation & Earnings

This table compares Bluejay Diagnostics and TransMedics Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85 million	($11.63)	-0.42
TransMedics Group	$605.49 million	4.16	$190.29 million	$4.40	16.57

TransMedics Group has higher revenue and earnings than Bluejay Diagnostics. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Summary

TransMedics Group beats Bluejay Diagnostics on 13 of the 13 factors compared between the two stocks.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

About TransMedics Group

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.